Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

ients have had a maximum Grade 1 QTc interval prolongation, and 7 patients a maximum Grade 2; the increases were clinically asymptomatic and not associated with AEs or dose reduction or delay. One patient who experienced an event of asymptomatic Grade 3 QTc interval prolongation had ineligible baseline QTc values (Grade 2) and was withdrawn from the study. A total of 16 serious AEs were reported in 8 patients. 5 events in 4 patients were considered possibly or probably related to study drug: Grade 3 GI hemorrhage and duodenal ulcer in 1 patient, and Grade 3 pneumonia, Grade 4 pulmonary embolism, and Grade 2 haemoptysis.

About XL647

XL647 is a potent inhibitor of receptor tyrosine kinases (RTKs) that are implicated in driving tumor proliferation and vascularization (blood vessel formation). XL647 inhibits EGFR, HER2 and VEGFR2. The compound has been optimized for high potency and oral bioavailability (using in vivo systems), demonstrates excellent activity in target-specific cellular functional assays and has shown sustained inhibition of target RTKs preclinically in vivo following a single oral dose. Two phase 2 trials in patients with NSCLC are ongoing.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at <
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... HIV detection using INSTI HIV-1/HIV-2 Antibody Test was accepted for presentation at the ... in Vancouver. The results will be presented Wednesday, July 22nd from 1:00 pm ...
(Date:7/7/2015)... , July 7, 2015  Neogen Corporation (NASDAQ: ... an agreement to expand its relationship with Illumina (NASDAQ: ... genomics. Under the agreement, Illumina will market and sell ... Infinium ® BeadArray technology, to the global agrigenomics ... agrigenomic customers through its GeneSeek ® genomics laboratory ...
(Date:7/7/2015)... July 7, 2015   Moleculera Labs ... matching grant from the Oklahoma Center for the ... supports the development and clinical validation of new ... neuronal antigens in patients experiencing neuropsychiatric disorders such ... are intended to assist physicians in identifying the ...
(Date:7/7/2015)... ... , ... The global aptamers market is expected to reach ... of 17.89% between 2015 and 2020. The aptamer type segments included in this ... report is segmented into diagnostics, therapeutics development, R&D, and other applications. Diagnostics applications ...
Breaking Biology Technology:bioLytical to Present Findings of Early HIV Detection 2bioLytical to Present Findings of Early HIV Detection 3Neogen signs commercialization agreement with Illumina 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5
... earnings from continuing operations during the first ... million US dollars ... All amounts in US dollars, QUEBEC CITY, May 6 /PRNewswire-FirstCall/ ... of,added value products for health and nutrition industries, announced today,his financial results ...
... MYERS, Fla., May 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) ... financial results on Wednesday, May 7, 2008., The ... their,Q1 08 results on May 7, 2008, at 11:00 AM ... 689-8565 (international) at least,five minutes prior to the call. ...
... 5 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a,company ... early,detection of diseases and personalized health management, today ... its Board of,Directors, Mr. Harry A. Glorikian and ... James Howard-Tripp, Mr. Garth MacRae, Dr. Heiner Dreismann, ...
Cached Biology Technology:Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2Genenews adds two members to its Board of Directors 2
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)... June 16, 2015 /CNW Telbec/ - handyem Inc. ... around the incorporation of handyem,s HPC-150 portable flow ... the Mo-POD™. This unprecedented model of mobile laboratory ... at the Pennsylvania Convention ... 15 th to 18 th 2015. ...
(Date:6/15/2015)... According to a new market ... Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & ... MarketsandMarkets, The Natural Language Processing Market is expected to ... for the forecast period 2015-2020. Browse ... igures spread   through 155 P ages and ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... new spring leaves up to 17 days earlier in the ... rise, according to a new study by Princeton University researchers. ... of northeastern forests and give a boost to their ability ... role in taking up carbon dioxide from the atmosphere, so ...
... reefs build their structures by both producing and accumulating ... and continued vertical growth capacity of reefs. An international ... carbonate being added by Caribbean coral reefs is now ... in some habitats is as much as 70% lower. ...
... have been named Charter Fellows of the National Academy ... and technological innovation. UH faculty members Benton Baugh, ... physics professor and chief scientist of the Texas Center ... professor in chemical and biomedical engineering, are among 101 ...
Cached Biology News:Spring may come earlier to North American forests 2Spring may come earlier to North American forests 3New evidence highlights threat to Caribbean coral reef growth 2New evidence highlights threat to Caribbean coral reef growth 3National Academy of Inventors honors 3 University of Houston professors 2National Academy of Inventors honors 3 University of Houston professors 3
Umbilical cord blood mesenchymal stem cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Biology Products: